Abstract Electronic cigarettes (e-cigarettes) are novel vaporising devices that, similar to nicotine replacement treatments, deliver nicotine but in lower amounts and less swiftly than tobacco smoking. However, they enjoy far greater popularity than these medications due in part to their behaviour replacement characteristics. Evidence for their efficacy as cessation aids, based on several randomised trials of now obsolete e-cigarettes, suggests a modest effect equivalent to nicotine patch. E-cigarettes are almost certainly far less harmful than tobacco smoking, but the health effects of long-term use are as yet unknown. Dual use is common and almost as harmful as usual smoking unless it leads to quitting. Population effects, such as re-normalising smoking behaviour, are a concern. Clinicians should be knowledgeable about these products. If patients who smoke are unwilling to quit or cannot succeed using evidence-based approaches, ecigarettes may be an option to be considered after discussing the limitations of current knowledge.
Introduction
Helping people to quit smoking tobacco is one of the most cost-effective interventions physicians can undertake [1] . However, the tools available to support smokers to quit are only modestly effective; long-term quit rates in smokers given gold standard cessation support (cessation medications and behavioural support) are at best around 20-30 % [2, 3] , leaving at least two thirds of smokers who use support to make a quit attempt continuing to smoke tobacco. Furthermore, these treatments do not help smokers unwilling to try them or smokers unwilling to make a quit attempt [4] . New approaches to cessation support that have wider appeal and greater efficacy are urgently needed.
In 2004, a novel nicotine delivery device emerged that promised to be a 'game changer' for smoking cessation. Electronic cigarettes, commonly known as e-cigarettes, were first developed in China in 2003. Unlike tobacco cigarettes, ecigarettes involve no combustion of tobacco. When users apply suction to the mouthpiece or, on some models, press a button, a heating coil is activated, vaporising a solution generally comprising propylene glycol, vegetable glycerine, nicotine and flavors.
E-cigarettes are now widely available throughout the world [5] . They have raised many concerns and questions and provoked debate and even division within the medical community about their place in tobacco control [6••] .
The rapid growth in e-cigarette sales was fuelled initially by a strong user (vapers) subculture [7] and well connected via social media, together with several well-organised consumer advocacy and e-cigarette industry organisations [8] . However, in the past few years, the tobacco industry has acquired most of the leading e-cigarette companies, and marketing has intensified. Much of it is remarkably similar to tobacco marketing prior to the imposition of smoke-free restrictions [9] . Unsurprisingly, awareness of e-cigarettes has increased dramatically, from 16 % in a US health survey conducted in 2009 to 32 % in 2010 [10] to almost 80 % in 2013 [11] .
Hand in hand, use of e-cigarettes among smokers has increased significantly; in the USA, its use has risen from 3 % in 2010 to between 20 and 30 % in 2012, the level varying on survey methods used [12, 13•] . E-cigarette use among nonsmokers remains very low but is nevertheless increasing, raising concerns about long-term use and dependence and potentially encouraging the transition by some to tobacco smoking (the gateway hypothesis) [14] . Adolescents typically enjoy experimentation and may consider e-cigarettes as a symbol of rebellion, sophistication and novelty to be tried [14] . Indeed, studies to date show increasing levels of experimentation with e-cigarettes among young people. For example, the US National Youth Tobacco Surveys in 2011 and 2012 collected data on self-reported e-cigarette use (defined as ever use, even a single trial), finding ever use doubled from 3.3 to 6.8 % among all students in grades 6-12, while current e-cigarette use increased from 1.1 to 2.1 %; current use of both e-cigarettes and tobacco cigarettes doubled from 0.8 to 1.6 % (p<0.05) [15] .
There are now hundreds of brands of e-cigarettes and an equally large array of solutions available in the USA alone. Zhu et al. reported finding 466 brands of devices and 7,764 unique flavours in an Internet search in January 2014 [16] . Ecigarettes vary in their operating features, performance and appearance. Some devices are almost indistinguishable from cigarettes (so-called cigalikes). Others look like pens and even perfume bottles. Some have sealed disposable cartridges, while others have refillable liquid reservoirs, topped up with bottles of e-liquid. In common to all are the following features: an aerosol generator, a flow sensor, a battery and a solution storage area [17] .
People report using e-cigarettes for a variety of reasons, but among the most consistently reported are to try to quit smoking, to use a product healthier than cigarettes, to avoid smoking restrictions, to cut down the number of cigarettes smoked and to save money [18] [19] [20] . A key question for clinicians and public health authorities, then, is "what is the evidence that e-cigarettes help smokers to quit?" This question can be addressed indirectly through studies of nicotine delivery and withdrawal reduction, of motivation to quit, and surveys of users and smokers, but more directly and robustly, through randomised controlled trials and large population studies.
Nicotine Delivery
Nicotine has the remarkable ability of binding to nicotinic acetylcholine receptors (nAChRs) in the human brain, triggering a chain of effects on the dopamine-glutamate and adrenergic systems [21] . Nicotine depolarizes the receptors for longer than acetylcholine, stimulating them before blocking them. In response, the brain up-regulates the number of nAChRs [22] . When nicotine administration stops, the upregulated nAChRs trigger aversive withdrawal symptoms.
However, over several months off nicotine, the number of receptors returns to normal. This understanding forms the scientific basis for using nicotine-based smoking cessation treatments. By replacing the nicotine obtained from tobacco smoke, they help mitigate withdrawal, easing the transition from tobacco and, hence, reducing the likelihood of relapse to smoking [23] .
Is there evidence that e-cigarettes may act in the same way? The first scientific studies to evaluate e-cigarettes found that they were about as effective at delivery of nicotine into the bloodstream as the medicinal nicotine inhaler [24, 25] . Subsequently, studies using newer, more efficient and reliable devices, with more experienced users, have found greater nicotine delivery in vapour than these earlier studies [26, 27] . Some e-cigarette vapour particles are small enough to penetrate deep into the respiratory tract, enabling swift nicotine absorption into the pulmonary venous circulation as occurs with tobacco smoke [28] . Salivary levels of cotinine at similar levels to those of tobacco smokers have been noted in e-cigarette users, indicating that effective absorption has occurred [29] .
However, e-cigarettes vary from brand to brand and model to model in their ability to produce an aerosol and deliver nicotine [30] . Nicotine yields from automated smoking machines suggest that e-cigarettes deliver less nicotine per puff than traditional cigarettes [31] . User behaviour, such as puff duration, is another important variable [32] . Despite almost a decade of product development and innovation, a recent study on a new-generation e-cigarette found nicotine delivery to be half that of a tobacco cigarette and almost 60 % lower than a medical nicotine inhaler [33] .
Tobacco Withdrawal Symptom Relief
Several studies in smokers naive to e-cigarette use compared e-cigarette performance with that of tobacco cigarettes [26, 34] [25] and with cigarettes and medicinal nicotine inhaler [24] . When participants used e-cigarettes, they experienced attenuation of withdrawal symptoms commensurate with using nicotine replacement therapy (NRT), despite negligible or very low levels of nicotine delivery, and far less swiftly than when smoking their usual cigarettes. Dawkins et al. in the UK randomised 86 smokers to 18 mg nicotine e-cigarettes or 0 mg e-cigarette or to just hold the e-cigarette; they then asked participants to rate their desire to smoke and withdrawal symptoms at baseline, 5 and 20 min after using the ecigarette ad libitum for 5 min [35] . At 20 min, desire to smoke and some aspects of nicotine withdrawal were significantly reduced in the nicotine and placebo group, compared with the 'just hold' group, suggesting that the conditioned smokingrelated cues that e-cigarettes provide may play a role in withdrawal mitigation.
Nicotine undoubtedly plays a central role in tobacco dependence [23] , but it is not the sole factor. For instance, Dale et al. found that even when nicotine patches were used in high doses (up to 44 mg per day) to replace the nicotine from cigarettes, titrated with blood cotinine levels, cessation efficacy was still modest [36] . Studies of reduced nicotine cigarettes have found that they can reduce craving [37] , and in a brain imaging study, Brody et al. found that smoking denicotinized cigarettes, leading to substantial brain nAChR occupancy [38] . Furthermore, despite medicinal nicotine's wide availability, relatively few people develop long-term dependence on nicotine replacement products; a UK study found long-term use of 2 % for patches and 13 % for nasal spray [39] .
In short, there appears to be more to cigarette dependence than merely nicotine. Other constituents of tobacco smoke, such as monoamine oxidase inhibitors, may play a role [40] . However, it is also likely that smoking-related stimuli, such as throat stimulation [37] and other sensory attributes of cigarettes, contribute to smoker satisfaction, product acceptance and puffing behaviour [41] . The use of the cigarette itself and the psychosocial and cultural aspects of smoking are likely to be more important in dependence than has been thought the case to date. These features may explain in some part, why, despite variable ability to deliver nicotine, e-cigarettes have become so popular with smokers.
Motivation to Quit
Other evidence is emerging. Wagener et al. measured readiness and confidence to quit smoking, nicotine withdrawal symptoms, product preference and satisfaction and smoking behaviour in a small group of cigarette smokers with no prior use of e-cigarettes and with no interest in quitting. The participants were given three e-cigarette brands and their own brand of cigarette to try and use for a week. Readiness and confidence to quit increased during the experimental stage and with ad libitum use, but no significant differences in reducing urges and cravings were found between the participant's own brand cigarettes and e-cigarettes, although own brand cigarettes were more enjoyable and satisfying. During ad libitum ecigarette use, regular cigarette smoking almost halved from baseline levels [42] .
Efficacy in Smoking Cessation
Evaluating the cessation potential of e-cigarettes is challenging. First, there is a rapidly changing and growing array of ecigarettes, with new designs and liquids, including a wide range of nicotine concentrations and flavors, emerging almost daily. As soon as a product is chosen for assessment and a trial set-up, it is near enough to obsolete and the findings, therefore, are of limited use. Second, most products lack instructions for users to ensure the optimal pattern of dosing, most likely to produce benefits while minimizing side effects, and are typically used without behavioural support. Most information for users is found on vapers websites. Third, many people use these products while continuing to smoke tobacco cigarettes. To date, no studies of such dual use beyond 12 months have been done to assess if the number of cigarettes smoked declines over a longer time frame than used to measure cessation efficacy in standard nicotine replacement therapy trials and how long e-cigarette use continues once cigarette smoking stops.
Early e-cigarette user surveys conducted online raised hopes that e-cigarettes might be significantly more effective at helping people to quit smoking than current approaches [18, 43] . However, it is likely that the participants were mostly 'converts', biasing the results in favour of e-cigarettes. Other surveys did not show a significant advantage in cessation with the use of e-cigarettes compared to no use of e-cigarettes, although these studies have a number of limitations [19, 44] .
Several case reports and small prospective studies of smokers not willing to quit and a pilot study for a full randomised controlled trial among smokers unwilling to quit pointed to the potential of e-cigarettes as cessation aids [45] [46] [47] . Quit rates in these studies were similar to those of the effects on cessation of nicotine replacement therapy use in smokers unwilling to quit.
To date, only two randomised controlled cessation trials of e-cigarettes have been published. The first of these trials, published in mid-2013 [48••] involved 300 healthy Italian smokers of at least ten cigarettes per day who were not interested in quitting, randomised to one of three groups: group 1 received 7.2 mg nicotine cartridges for 12 weeks, group 2 received a 6-week supply of 7.2 mg nicotine cartridges then a further 6-week supply of 5.4 mg nicotine cartridges, and group 3 received 0 mg nicotine cartridges for 12 weeks. Over 1 year of follow-up, nine visits were undertaken to measure cigarettes smoked and exhaled breath carbon monoxide (CO) levels. Minimal support was offered. The researchers found similar reductions in smoking between the three groups, and CO-verified cessation rates at 12 months after the quit date were around 9 %, with no cessation advantage of nicotine e-cigarettes over placebo e-cigarettes [48••] . Limitations of this trial included the unusual design for a cessation efficacy end point study, the lack of statistical power, high loss to follow-up (40 %) at 12 months and use of a now obsolete product, having been superseded by more reliable and possibly better performing devices.
Also in 2013, the findings from a large randomised controlled efficacy trial conducted in New Zealand were published [49••] . This trial compared the use of e-cigarettes with and without nicotine, versus nicotine patches, in 657 healthy adult smokers wanting to quit smoking. Participants were randomised in a 4:4:1 ratio to 16 mg nicotine e-cigarettes (n= 289), nicotine patches (21 mg patch, once daily, n=295) or placebo e-cigarettes (containing no nicotine, n=73), from 1 week before until 12 weeks after quit day, with lowintensity behavioural support available as desired through a free telephone counselling line. The primary outcome was CO-verified continuous abstinence at 6 months. At 6 months, verified abstinence was only 7.3 % in the nicotine e-cigarette group, 5.8 % in the patches group and 4.1 % in the placebo ecigarette group, but these differences did not achieve statistical significance. Limitations of this study included insufficient statistical power to conclude superiority of nicotine ecigarettes to patches or to placebo e-cigarettes, an unreliable study product (frequent battery failure) and an uneven loss to follow-up. The researchers concluded that e-cigarettes, with or without nicotine, were only modestly effective at helping smokers to quit, with similar abstinence rates as nicotine patches. However, participants who used e-cigarettes rated them highly.
These two trials were pioneering, but their limitations make the findings difficult to generalise, and they provide insufficient evidence for regulatory authorities to recommend them as efficacious cessation treatments. Population-based studies in the real world provide further insights into the cessation potential of e-cigarettes. Using representative samples of adults for population surveys in 2010 (n=12,597 adults, including 2,297 smokers) and 2012 (n=12,432 adults, including 2,093 smokers), Dockrell et al. in the UK found 1.1 % of ex-smokers in 2012 reporting current e-cigarette use and a further 2.7 % reporting past use, supporting the view that e-cigarette use may be a bridge to quitting [50] .
More recently, Brown et al., also in the UK, published the findings from a cross-sectional survey of 5,863 English adults who had smoked within the previous 12 months and made at least one quit attempt during that period [51••] . The researchers found that, after adjusting for a range of potentially confounding smoker characteristics including nicotine dependence, e-cigarette users were 63 % more likely to report abstinence than those who used nicotine replacement treatments purchased over the counter and 61 % more likely than those who had no quitting support. Related findings from the Smoking In England Study suggest that recent smoking prevalence declines in England could be attributable, at least in part, to the widespread use of e-cigarettes and the resulting increased success at quitting smoking [52••] .
In summary, the available evidence from randomised trials suggests at best that e-cigarettes perform no better than nicotine patches as cessation aids in the absence of intensive behavioural support. However, newer products may be more efficacious, and the addition of support is likely to improve outcomes, as with nicotine replacement treatments. Real world population studies also point to e-cigarettes being able to assist smokers to quit, with much of the effect likely due to the use characteristics of e-cigarettes rather than nicotine delivery. Adequately powered randomised trials of newgeneration products that are more reliable and more efficient in delivery of nicotine are urgently needed to more adequately assess the cessation potential of these devices.
E-cigarettes and Harm Reduction
E-cigarettes have potential to provide an alternative to tobacco use for people unwilling or unable to quit smoking and, in so doing, serve as a substitute dependency [53] . Whether a harm reduction approach to tobacco control delivers overall population health gain is a key debate that e-cigarettes have provoked in the tobacco control community.
Based on current evidence, nicotine delivery in e-cigarette vapour is far safer than nicotine delivery in tobacco smoke. However, if the use of e-cigarettes delayed cessation in people who would have otherwise quit smoking, who use them just to manage situations where they cannot smoke or who perceive that they are reducing harm by smoking fewer cigarettes, the net harm could be greater [6••] . Against this is the finding in the study by Dockrell et al. that people who used e-cigarettes in situations where they could not smoke were more likely to have tried to stop in the recent past than those who did not [50] .
Nevertheless, many people taking part in surveys report using e-cigarettes to reduce harm or risks to their health by substituting e-cigarettes for some, not all, of the tobacco cigarettes they usually smoke [43, 54, 55] . In the two trials of e-cigarettes for cessation, among participants who did not quit, around 10 % reduced their cigarette consumption by around 50 % [48••, 49••]. The extent to which cutting down tobacco smoking (using e-cigarettes as cigarette substitutes) leads to cessation is not known, but in a recent pilot study, Lechner et al. found that with increased duration of e-cigarette use, fewer cigarettes were smoked per day [56] , suggesting the possibility that if participants were followed over longer time than it typically done in smoking cessation studies (usually 6-12 months), complete tobacco cessation could well be achieved.
Effects on User Health
Much is known about the impact of tobacco smoking on health, based largely on cohort studies undertaken over many decades [57, 58] , but relatively little is known of the health consequences of e-cigarette use. This reflects the short time ecigarettes that have been available and the unavailability of research funding from industry and public good funders to support such post-marketing surveillance.
The health effects of nicotine are well described. Nicotine is potentially lethal in overdose, but its role in causing other diseases, including cardiovascular disease, is probably a minor one [21] . Medicinal nicotine causes transient increases in blood pressure and heart rate, but epidemiological studies have found no association with the development of cardiovascular disease [59, 60] . A study evaluating the safety of nicotine patches in 584 patients with coronary disease found no increase in the risk of adverse cardiovascular events over 14 weeks of use [61] . In comparison with continued smoking, the risks of nicotine replacement in smokers, even those with cardiovascular disease, are exceedingly small [62] .
It is likely that any adverse health effects in e-cigarette users are due to the non-nicotine constituents of e-cigarette vapour. In the absence of long-term studies, data on toxicants in e-cigarette refill solutions, cartridges, aerosols and environmental emissions provide insights into potential hazards. Potentially toxic substances such as tobacco-specific nitrosamines, aldehydes, metals, volatile organic compounds, phenolic compounds, polycyclic aromatic hydrocarbons, flavours, solvent carriers, tobacco alkaloids and drugs have all been detected but at widely varying levels, generally far below those in tobacco smoke and sometimes no greater than those in medicinal nicotine products [63•] . Ultrafine particulate matter with different particle size distribution ranges has been reported in e-cigarette aerosols and emissions [64] . However, the methods used for the generation and chemical analyses of e-cigarette aerosols vary across studies [63•] . The lack of standardization, together with the different performance characteristics of different products, makes the assessment of the toxic potential of e-cigarettes difficult.
In a recent review of the literature on e-cigarettes and health, Callaghan-Lyon analysed data from 44 articles, finding that e-cigarette vapour contained fewer toxicants than cigarette smoke but noting also that data on short-and long-term health effects were inadequate to make an assessment [65• ].
Short-term effects from inhalation of propylene glycol and glycerol included mouth and throat irritation and transient respiratory function impairment. No data were found on the health effects of inhaling flavourings. The review found that while studies evaluating the relative harmfulness of e-cigarettes and cigarettes are inconclusive, the health effects of e-cigarette use are unlikely to be as severe.
To date, few studies have specifically examined the effects of e-cigarettes on health, and fewer specifically on cardiovascular function; in those that have explored cardiovascular effects, the expected response to nicotine has been found, with no evidence of harm [34] .
On balance, the major concerns should not lie so much with the potentially harmful constituents in e-cigarette vapour but with the known harms of continued tobacco smoking, which is common in e-cigarette users. As noted, smoking reduction with e-cigarettes may lead ultimately to cessation, but smoking even a few cigarettes a day is hazardous, dramatically increasing the risk of an acute cardiovascular event, compared to never smoking [66] . Therefore, in patients with a history or at a high risk of cardiovascular disease, the priority must be encouraging rapid progress towards complete smoking cessation.
Regulation
The emergence of e-cigarettes has found current regulatory frameworks wanting. Policies and regulations should include balanced assessment of the net benefits and risks of ecigarettes at both individual and population levels ( Table 1) . The harms of e-cigarettes for individuals, at least in the short term, appear to be few. It will be many years before it is known if there are long-term harms from ongoing use, but it is unlikely that they will be any worse than those from smoking tobacco. The greater potential for net harms is likely to be at the population level. While e-cigarettes could contribute to reducing smoking prevalence if sufficient numbers of people use them to successfully quit smoking, and could reduce exposure to toxic second-hand tobacco smoke, they also have potential to harm through delaying cessation, acting as a gateway to tobacco smoking in non-smokers or triggering relapse back to smoking in ex-smokers.
Regulation should be based on the best scientific evidence available. In the absence of good evidence on many aspects of e-cigarettes, interim measures-such as those ensuring standards for product quality and safety, contents, emissions and labelling and prohibiting marketing and sales to young people-should be introduced. However, the regulatory pendulum should not swing so far as to restrict availability to smokers who have found them to be the only product that has helped them quit smoking and remain abstinent (Table 1 ).
Clinical Advice
Clinicians should take every opportunity to strongly encourage their patients who smoke tobacco to stop and should assist them in their quit attempts using the evidence-based cessation treatments and behavioural support available. Indeed, it has been argued that this is an ethical imperative [67] . Inevitably, some patients will ask about e-cigarettes. Indeed, many are likely to have tried them or to be using them. Patients should be informed that they are probably as effective as nicotine patches and almost certainly a far safer option than continuing to smoke tobacco, but that there is a lack of sound evidence on long-term safety and efficacy. On that basis, patients who are unwilling to quit smoking or who have tried the range of evidence-based approaches available yet relapsed to smoking should not be actively stopped from trying or continuing to use e-cigarettes. Rather, they should be offered support to quit and advised that if they do use e-cigarettes, it is safest that they are used without continuing to smoke tobacco, even one cigarette.
Conclusions
Current evidence suggests that e-cigarettes are only modestly effective at helping smokers quit, but with such wide popularity, they may contribute to reducing population smoking prevalence. However, dual use with tobacco is common and could prolong harmful exposure to tobacco smoke. Ecigarettes also have potential to renormalise smoking behaviour. Balancing their potential for benefit and harm at individual and population levels in the face of a rapidly changing market is challenging for researchers, clinicians and regulators. The harms of short-term use appear limited, and they are almost certainly less harmful than continuing to smoke. Clinicians should use every opportunity to advise smokers to quit and so may consider e-cigarette use for patients unwilling to stop smoking or for whom evidencebased treatments have failed.
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